Evaluating scope and bias of population-level measles serosurveys: a systematic review and bias assessment 3

- Alyssa N. Sbarra, MPH^{1,2*}, Prof. Felicity T. Cutts, MD¹, Han Fu, PhD¹, Ishu Poudyal,
 BA², Dale Rhoda, M.S. ³, Jonathan F. Mosser, MD^{2,4†}, Prof. Mark Jit, PhD^{1†}
- 6
- ¹ Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical
 Medicine, London, UK
- 9 ² Institute of Health Metrics and Evaluation, University of Washington, Seattle, WA, USA
- ³Biostat Global Consulting, Worthington, OH, USA
- ⁴ Department of Health Metrics Sciences, University of Washington, Seattle, WA, USA
- 12
- 13 † Authors contributed equally
- 1415 * Corresponding author
- 16 alyssa.sbarra@lshtm.ac.uk

17 Abstract

18

Background: Measles seroprevalence data has potential to be a useful tool for understanding
 transmission dynamics and for decision making efforts to strengthen immunization programs. In
 this study, we conducted a systematic review and bias assessment of all primary data on
 measles seroprevalence in low- and middle-income countries published from 1962 to 2021.

23

Methods: On March 9, 2022, we searched PubMed for all available data. We included studies
 containing primary data on measles seroprevalence and excluded studies if they were clinical
 trials or brief reports, from only health care workers, suspected measles cases, or only
 vaccinated persons. We extracted all available information on measles seroprevalence, study

- design, and seroassay protocol. We conducted a bias assessment based on multiple categories
 and classified each study as having low, moderate, severe, or critical bias. This review was
 registered with PROSPERO (CRD42022326075).
- 31
- 32 <u>Findings:</u> We identified 221 relevant studies across all World Health Organization regions,
- decades and unique age ranges. The overall crude mean seroprevalence across all studies was
- 34 78.00% (SD: 19.29%) and median seroprevalence was 84.00% (IQR: 72.75 91.66%). We
- classified 80 (36.2%) studies to have severe or critical overall bias. Studies from country-years
 with lower measles vaccine coverage or higher measles incidence had higher overall bias.
- 37

Interpretation: While many studies have underlying bias, many studies provide data that can be
 used to inform modelling efforts to examine measles dynamics and programmatic decisions to
 reduce measles susceptibility.

41

Funding: Bill & Melinda Gates Foundation; Gavi, the Vaccine Alliance; US National Institutes of
 Health

44 Research in Context

45 Evidence before this study

46 On August 20, 2023, we searched PubMed for systematic reviews published from January 1, 47 1980 to August 20, 2023 using the search terms "measles" AND "sero*". We included studies if 48 they were a systematic review of measles seroprevalence data and excluded studies that did 49 not contain information on measles seroprevalence, were not systematic reviews, only included 50 data from persons within a subpopulation (e.g., pregnant people or healthcare workers), or were 51 of head-to-head laboratory comparisons of assay methodology. We identified one previous 52 systematic review, by Thompson and Odahowski, published in 2016 and including data through 53 mid-2014. That review identified 220 measles and/or rubella seroprevalence studies from all 54 countries globally. Study authors published a descriptive summary of seroprevalence trends by 55 age in a five select countries and a narrative summary of high-level epidemiologic trends in the 56 underlying data, including information available on maternal antibody waning. Beyond these 57 select summary findings, that study did not separately report seroprevalence from each study 58 identified in the analysis, nor did it include any information on study design or population-59 representativeness. While study authors noted general limitations related to the different 60 methods used across studies, they did not include any specific information on assay type, 61 selection biases or other characteristics that could influence the accuracy of results or include 62 data in a tabular format, which limits the utility of this study for subsequent analyses.

63

64 Added value of this study

65 Our study builds upon the known body of data on measles seroprevalence from low- and

66 middle-income countries in multiple ways. First, we included data published up to December 31,

67 2021 and from non-English language studies. Second, we extracted all available relevant

68 information on study design characteristics and assay protocol used in each study to measure

69 seroprevalence. Then, we constructed a bias assessment framework and conducted a bias

assessment across multiple categories (study selection of participants, measurement tool and

classification of immunity, and reporting of results) to classify the underlying bias in each study.
 Finally, we compared seroprevalence estimates across regions and bias levels, and bias levels

- Finally, we compared seroprevalence estimates across regions and bias levels, and bias levels among various study location characteristics.
- 74

75 Implications of all the available evidence

76 Accounting for study design and seroassay protocol used in serosurveys can influence

77 interpretation of population-level seroprevalence estimates. Our systematic review and bias

78 assessment provides an updated landscape of serological studies and highlights key biases in

the current literature. It provides a repository of measles seroprevalence data, along with

80 corresponding critical information on factors that influence population-representativeness and

81 overall sensitivity of the measurement assay used in each study, that can be used to inform

82 measles susceptibility estimates useful for planning targeted vaccination efforts.

84 Introduction

Measles remains a substantial cause of global morbidity and mortality¹, especially in low- and
 middle-income settings where over 99% of measles cases and deaths occur², despite the
 availability of a safe and effective vaccine³. Because ongoing measles transmission can be

- 88 maintained if herd immunity (i.e., when the proportion of the population immune is sufficient to
- 89 limit disease spread) has not been reached and sustained, estimating the proportion of people
- 90 susceptible within a community is essential to plan immunization programs and assess future
- risk of measles outbreaks and deaths. However, due to factors such as timeliness of and age at
- 92 vaccination⁴, disruptions to cold chains⁵, a lack of seroconversion in specific subpopulations
- (e.g., among persons living with human immunodeficiency virus (HIV)⁶), and variable
 surveillance systems across locations and time, inferring population-level measles immunity
- 94 surveillance systems across locations and time, interring population-level measies immunity 95 from a combination of vaccination coverage and case notifications can be challenging⁷.
- 96 Alternatively, serosurveys can provide a snapshot of immunity gaps that remain in a community
- 97 by determining population-level prevalence of IgG antibody levels above specific thresholds that 98 suggest clinical protection against disease.
- 99

100 As such, seroprevalence data can be used as tools to guide decisions to and strengthen

101 immunization programs, as inputs to dynamic models of disease transmission, and additionally

to provide insights into vaccine field effectiveness and assessment of case ascertainment

- rates^{7,8}. The interpretation of seroprevalence data is complicated, however, because of the
- 104 potential for bias. Some of this bias can be due to inadequate sensitivity of laboratory assays⁹
- and/or specimen types¹⁰ used for measuring antibody levels. Additionally, bias from assay
 procedures can be suspected when protocols or commercial details are not reported or if no
- 107 quality control was performed. Furthermore, population-based surveys have the potential for
- additional bias to be introduced in the selection of participants or from lack of
- 109 representativeness of the selected sample from the community.
- 110

111 Beyond understanding the selection processes and laboratory assays used, it is critical to also 112 consider how results of the serosurveys are reported. Considerations include what threshold of

112 consider how results of the serosurveys are reported. Considerations include what threshold of 113 antibody titer was used as a correlate of clinical protection and how some tests report

113 antibody titer was used as a correlate of clinical protection and how some tests report 114 indeterminate results. In order to responsibly use and accurately interpret seroprevalence data

for decision making or for modelling exercises, these issues need to be transparently

- 116 acknowledged and discussed.
- 117

A more in-depth understanding of available seroprevalence data across locations and time, as well as the related implications, is critical for using these historic data to calibrate models used to inform decision making for immunization program strengthening, especially in low- and middle-income countries (LMICs) that face the highest ongoing measles burden. To fill these gaps, we first conducted a systematic review of literature reporting measles seroprevalence

- 123 data published through 2021 and extracted information on key study and assay information.
- 124 Then, we developed a pilot bias assessment tool to assess the risk of bias in each study across
- 125 the following categories: study selection of participants, measurement tool and classification of
- 126 immunity, and results reporting.
- 127

128 Methods

- 129 Search strategy and selection criteria
- 130 This study follows PRISMA guidelines (Supplementary Tables 1-2) and was registered with
- 131 PROSPERO (CRD42022326075). We performed a systematic review of published literature in
- any language containing information on population-level measles seroprevalence in LMICs. We

searched PubMed on March 9, 2022 for primary data published through December 31, 2021using the following search string:

- 135
- (((Measles) AND (seroprevalence OR sero-prevalence OR seropositive OR sero-positive
 OR seronegative OR sero-negative OR seroepidemiology OR sero-epidemiology OR
 seroprofile OR seroimmunity OR sero-immunity))
- 139 OR ("Measles/epidemiology"[MeSH] AND (antibod* OR serolog*)))
- 140 AND ("1900"[Date Publication] : "2021"[Date Publication])
- 141

One individual (ANS) screened titles and abstracts for each study in the search results. For
 relevant studies, one of multiple individuals (ANS, HF, IP) reviewed the full-text of each to
 determine their inclusion or exclusion. We included studies that contained original data on
 measles antibody prevalence and excluded studies if they only contained data from high-income
 locations (as based on WorldBank 2021 income classifications¹¹), did not contain data on

- 147 measles IgG antibody, were based on non-original data or from non-human subjects, contained
- 148 only results from laboratory assay development or clinical trials (including studies only
- 149 containing information on vaccinated persons), studied a target population of only health-care
- 150 workers or active measles cases, or were a review, abstract, letter, editorial or brief report.
- 151

152 Following full text review, for each study that met our inclusion and exclusion criteria, we

- extracted the following data: study setting, study design and type (including information on
 planned, achieved (i.e., how many persons were reached via sampling), and reported (i.e., how
- 155 many persons were represented in final study metrics) sample sizes), population demographics
- 156 (including income and representativeness), type of specimen collected, serologic assay details
- 157 (including type, name, and inclusion of a reference preparation), antibody threshold used for
- seropositivity and/or seroprotection (if relevant), and measures of proportion seropositive,
 seronegative, or indeterminate with accompanying uncertainty. We extracted data into a
- 160 Microsoft Excel workbook and for seroprevalence measure, we recorded the most granular
- 161 levels for relevant strata (i.e., by age, vaccination status, infection history, etc.) presented in
- 162 each study.
- 163
- 164 Bias assessment

Following extraction of all available data, we developed a comprehensive bias assessment tool and applied the tool to characterize the level of bias across each study. Our tool, modified from the ROBINS-I tool¹², considers bias across the following categories, with associated indicators: study selection of participants, measurement tool and classification of immunity, and reporting of results (Supplementary Figures 1-3). We classified the level of bias across each category to be either low, moderate, severe, or critical. We then finally assessed the overall level of bias as low, moderate, severe, or critical for each study by taking the mean score of the category-

- 172 specific classifications.
- 173
- To assess bias among study selection of participants, we considered whether the study design used a random process for sample selection, if a study relied on a convenience sample, was
- 176 restricted only to a subset of the population (e.g., only included pregnant women or cancer
- 177 survivors), and reporting of planned, achieved, specimen, and final sample sizes. To assess the
- 178 level of bias among the measurement tool and classification of immunity, we considered
- 179 whether assay protocol, name, or references were provided, if internal or external validation or
- 180 quality control was performed, and if there were other known factors known to decrease
- 181 sensitivity or specificity. These factors included using oral fluid as specimens¹³, using a homogenuities inhibition (H/HA) accounts the M/Hittelies entry as the test of tes
- hemagglutination inhibition (HI/HAI) assay¹³, or using the Whittaker enzyme-linked
- 183 immunosorbent assay (ELISA)¹⁴. Last, for bias among reporting of results, we considered

whether a known threshold was used for determining protective titer levels, including metrics of
 uncertainty with seroprevalence estimates, and, if an enzyme immunoassay (EIA) or ELISA was

- 186 used, whether and how equivocal results were handled and reported.
- 187

188 We characterized the overall level of bias in each study using the following criteria. For each

- 189 category of bias studies were given a numeric score: low bias was assigned a score of 1,
- 190 moderate a score of 2, severe a score of 3, and critical a score of 4. We took the mean of
- 191 scores across all three categories. Studies with a mean score below 1.5 were characterized to
- have low overall bias, between 1.5 and 2.5 to have moderate overall bias, between 2.5 and 3 tohave severe bias, and more than three to have critical bias.
- 193 194
- We converted all metrics reported to proportion seropositive and then used R version 5.4.0 to compute summary metrics and make figures. For studies reporting seropositive and indeterminate/equivocal results independently, we did not include indeterminate results in the numerator of our overall seroprevalence calculation. We compared data availability by decade and bias level. We additionally investigated bias levels across time and region and assessed bias levels across locations with higher and lower first-dose measles-containing vaccine (MCV1) coverage¹⁵ and higher and lower estimated annual measles incidence¹⁶ in the year from which
- 202 study data was collected.203

204 Role of the funding source

The Bill & Melinda Gates Foundation, Gavi, the Vaccine Alliance and the US National Institutes of Health had no role in study design, data collection, data analysis, data interpretation, or the writing of the report. All authors had access to the data and the corresponding author had final responsibility to decide to submit for publication.

209 210 Results

211 Systematic review

From our search, we identified 2032 studies for screening (Figure 1). Following screening, we excluded 1116 studies that did not meet our search criteria. For the remaining 916 studies, we assessed the full-text articles for inclusion. We identified 221 studies for inclusion and extracted information on measles seroprevalence, study design, and seroassay (link to zenodo file once

- 216 uploaded). Studies were published between 1962 to 2021, including seroprevalence surveys
- conducted between 1953 and 2019.
- 218

Among 182,789 persons sampled across all studies, age groups, and years, the crude mean measles seroprevalence was 78.00% (SD: 19.29%) and median seroprevalence was 84.00% (IQR: 72.75 – 91.66%).

Across regions of the World Health Organization (WHO), there were 43 studies containing data from the African Region, 47 from the Eastern Mediterranean Region, 35 from the European Region, 25 from the Region of the Americas, 20 from the South-East Asia Region, and 73 from the Western Pacific Region (Figure 2). There were 24 studies that represented data collected before 1980, 32 studies from 1980 to 1989, 29 studies from 1990 to 1999, 55 studies from 2000

- to 2009, and 83 studies from 2010 to 2019. 178 studies (80.5%) contained age stratified results across 531 unique age ranges.
- 229
- 230 Bias assessment
- Table 1 shows results of our bias assessment for each included study. For overall bias, we
- classified bias as low in 12 (5.4%) studies moderate in 129 (58.3%), severe in 58 (26.2%) and
- critical in 22 (10.0%). No studies had low or critical bias across all the categories of study

selection of participants, measurement tool and classification of immunity, and reporting ofresults (Table 1).

- For study selection of participants, we identified 15 studies with low bias, 181 with moderate
 bias, 23 with severe bias, and 2 with critical bias. 81 studies used a random sample selection
 method. 117 studies with convenience samples used a restricted, non-representative sample
 (i.e., only among a specific subgroup of the population, such as persons living with HIV). 2
 studies did not report the final sample size, and of the 81 samples that used a random sample
 selection method, 45 reported the planned sample size, and 15 additionally reported the
 planned, achieved, and specimen sample sizes.
- 244 245 In measurement assay and classification of immunity, we identified 19 studies with low bias, 130 246 with moderate bias, 46 with severe bias, and 26 with critical bias. Across the three categories of 247 bias assessment, measurement assay and classification of immunity had the highest number of 248 studies classified as having critical bias, largely due to absence of information on assay protocol 249 details, commercial kit name or other appropriate citation describing the underlying methods. 250 195 studies provided details on the assay protocol or commercial kit name, and 25 studies 251 conducted internal or external validation or quality control. 6 studies specified that samples were 252 oral fluid specimens and 30 studies specified that samples collected were dried blood spots. 253
- 54 studies used an HI/HAI assay, 139 used an EIA or ELISA, 13 used a plaque reduction
 neutralization test (PRNT), 6 used a multiplex bead assay, and 11 used other or undescribed
 assay types. We noted changing temporal trends of types of seroassays used. While EIA,
 ELISA and PRNT assays were used in even distribution across all studies examined, there was
 no study published after 2001 that utilized an HI/HAI assay, and all studies using a multiplex
 immunofluorescent assay were conducted in 2013 or later.
- We identified 20 studies with low bias, 63 with moderate bias, 70 with severe bias, and 18 with critical bias in reporting of results. 155 studies reported a threshold to define seroprevalence. Among the 139 studies that used an EIA or ELISA, 30 studies reported equivocal results separately or included with seropositivity results and 1 study excluded equivocal results and they were less than 5% of the overall sample. Finally, 59 studies reported metrics of seropositivity or seronegativity with any accompanying uncertainty.
- 268 Seroprevalence trends
- 269 The crude median seroprevalence estimates from studies in the Western Pacific Region was 270 88.3% (IQR: 79.2 – 93.4%), in the Eastern Mediterranean Region was 87.2% (IQR: 81.3 – 271 93.2%), the European Region was 82.0% (IQR: 77.8 – 89.0%), in the Region of the Americas 272 was 78.4% (IQR: 60.7 – 93.0%), in the African Region was 77.6% (IQR: 60.7 – 89.9%), and in 273 the South-East Asia Region was 66.8% (IQR: 47.4 – 88.4%). Trends in seroprevalence and bias 274 vary by decade (Figure 3). The median seroprevalence was lower in studies from 2010 to 2019 275 than those conducted before 1980 (i.e., the pre-vaccination era). Crude seroprevalence from 276 studies conducted before 1980 was 90.5% (IQR: 67.8 – 93.3%), from 1980 to 1989 was 78.6% 277 (IQR: 57.8 – 90.7%), from 1990 to 1999 was 88.3% (IQR: 60.7 – 92.6%), from 2000 to 2010 278 was 80.4% (IQR: 65.6 - 88.2%), and from 2010 to 2019 was 84.6% (IQR: 78.3 - 92.9%). 279 Among 31 country-years with studies containing critical bias, 23 (74%) occurred in earlier time 280 periods (i.e., before 1980 and between 1980 and 1989). In the 159 country-years with studies 281 containing low or moderate bias, 96 (60%) have occurred between 2010 and 2019.
- 282

We additionally compared the overall bias levels for each country-year of the studies to the MCV1 coverage and measles incidence from the same country-year (Figure 4). Generally,

285 studies in countries and years in 1980 or later with lower MCV1 coverage and higher measles 286 incidence had more bias compared to studies from countries and years with higher MCV1 287 coverage and lower measles incidence (p < 0.001, in proportional odds logistic regression 288 models for both MCV1 coverage and incidence). Among 109 studies from countries and years 289 with MCV1 coverage greater than 80%, 93 (85%) had low or moderate overall bias, and from 290 the 58 studies from countries and years with MCV1 coverage of 80% or lower, 34 (58%) had 291 low or moderate overall bias. A similar trend persisted across studies in countries and years 292 with high incidence – 103 of 122 (84%) studies in countries and years with average annual 293 reported measles incidence less than 5 per 1000 persons had low or moderate overall bias, and 294 24 of 49 (49%) of studies in countries with annual measles incidence of 5 per 1000 persons or 295 greater had low or moderate overall bias. 296

297 Discussion

298 To identify the scope of measles seroprevalence data, we conducted an updated systematic 299 review of serosurveys to identify primary data sources and characterized underlying bias across 300 these studies. The resulting data repository from our investigation along with information on 301 factors related to underlying bias per study could contribute to analyses of measles dynamics 302 among low- and middle-income countries. We identified serosurveys available in each decade, 303 WHO region, and across a wide variety of ages, which could be useful when modelling location-304 , time-, and age-specific estimates of measles transmission and susceptibility. Despite this 305 variation, there were locations for which very few or no serosurveys have been conducted -306 mainly in the African Region – which contribute to knowledge and data gaps to inform high-307 quality modelling and analyses. 308

309 Additionally, our study provides insight to issues to consider when designing and reporting a 310 seroprevalence study to ensure that the highest quality surveys are conducted and that 311 complete, accurate and transparent reports are generated. The number of available measles 312 seroprevalence studies has increased in the last few decades compared to periods before the 313 introduction of national measles vaccination programmes in LMICS. This trend provides the 314 opportunity for researchers to examine the impact of vaccination programs on ongoing 315 susceptibility within the population represented in each study. However, we found that locations 316 with high annual measles incidence and lower MCV1 coverage tend to have not only less 317 studies conducted, but also higher bias - this is understandable given that coverage tends to be 318 lower in the most difficult settings such as remote and/or conflict-affected regions, where 319 surveys are especially challenging to conduct. Research and programmatic teams planning 320 seroprevalence studies, especially among persons living in these vulnerable communities, could 321 use the framework presented in this study as a starting point to determining the feasibility and 322 cost of conducting a high-quality seroprevalence survey and consider alternative ways to invest 323 the funds (e.g., in strengthening ongoing surveillance of coverage and disease incidence). 324

325 More recently, there have been examples of high-quality serosurveys, such as a nationally 326 representative survey in Zambia¹⁷, that have been conducted and used for informative 327 modelling. Given the complexity, time, and expense of these surveys, it is worthwhile to make 328 the most of high-quality surveys that are being conducted for different infections and funded 329 through a variety of different programs. This serosurvey in Zambia, for example, leveraged 330 residual sera from the Zambia Population-Based HIV Impact Assessment (ZAMPHIA) study¹⁸ 331 originally collected to estimate HIV incidence and viral load. Applications of such data extend to 332 innovative modelling efforts to estimate subnational and age-specific seroprevalence estimates as well as national level outbreak risk¹⁷. That study serves as an example of the potential to 333

leverage other major population surveys and to use high quality seroprevalence estimates toinform evidence for decision making.

336

More studies had low or moderate bias compared to severe or critical bias among the categories of selection of study participants and measurement tool and classification of immunity. For the category of reporting of results, more studies had severe or critical bias levels than low or moderate bias levels. Overall, we found that less than 10% of studies had low overall bias, suggesting that the quality of conduct and reporting of seroprevalence studies has substantial potential for improvement.

343

344 While interpreting seroprevalence estimates identified by our review, it is essential to also 345 consider the associated sensitivity and specificity of the seroassays used in studies along with 346 the route of induced immunity (i.e., from vaccination or natural infection). For example, HI/HAI assays are often less sensitive than other types¹³. If HI/HAI assays are used in a population with 347 348 mainly vaccine-induced immunity, seroprevalence results may be underestimated. However, 349 since HI/HAI assays were historically used more frequently, during an era with less vaccine-350 derived immunity and subsequently higher natural immunity affording higher antibody levels, 351 assay sensitivity might not be as important to consider. In our bias assessment in the category 352 of measurement tool and classification of immunity, we defined factors that influence assay 353 specificity and sensitivity as either (1) using an HI/HAI assay, (2) using the Whittaker 354 commercial ELISA kit, or (3) using oral fluid samples. However, the utility of this specific 355 contribution to our bias assessment might be subject to the specific study setting, vaccination 356 program implementation and success, and underlying measles epidemiology. 357

358 Our study has several limitations. First, we were unable to fully synthesize results of our 359 systematic review in a meta-analysis or other stratified analysis by age, location, or year. This 360 was due to the differing study populations, regions, time periods, and age groups presented in 361 studies identified in this review as well as the varying degrees of bias characterized to be 362 present across studies. These results can serve as the basis for future models that synthesize 363 the data while also accounting for underlying measles infection dynamics, vaccination coverage 364 and population structures for each individual study setting, which was out of the scope of our 365 analysis. 366

367 Secondly, we were constrained by the information reported in each publication. Without 368 adequate reporting, we assumed the highest level of associated bias whenever appropriate. For 369 example, if a study did not specifically note if they used an international reference preparation, 370 we assumed they did not use one. This may have led us to classify studies as having higher 371 bias in relevant categories than might have been the case if all available information had been 372 included in the publication – it possible that some details were omitted to meet restrictions on 373 word counts, for example. As such, there might be great utility in the widespread use of 374 standardized reporting expectations for ongoing and future seroprevalence studies.

375

376 Next, we did not consider sample size in our assessment of bias. Since the impact of sample 377 size on the reliability of point estimates from seroprevalence studies should be reflected in the 378 provided uncertainty interval, we considered the inclusion of such in our bias assessment. We 379 did not however further assess the implications of smaller or wide interval spans of if they were 380 presented or whether point estimates or uncertainty intervals were adjusted or standardized for 381 population demographics or other factors. Finally, there are likely additional sources of bias that 382 are more difficult to ascertain objectively, such as potential issues with specimen storage and 383 laboratory capacity, practices, and quality. 384

- 385 Our study strengthens the understanding of the availability and bias among measles
- 386 seroprevalence studies in low- and middle-income countries by identifying primary sources of
- measles seroprevalence studies and conducting a bias assessment of the associated data. Our
- 388 framework for assessing bias could provide a foundation for further work by relevant agencies
- 389 and interested partners to develop a tool for use in planning and reporting future surveys. This
- 390 work can be a vital tool to be used during modelling exercises, planning immunization-based 391 interventions, and ultimately, to make informed decisions to reduce preventable measles
- 397 Interventions, and ultimatery, to make informed decisions to reduce preventable measies
- 392 morbidity and mortality.
- 393

394 Contributions

ANS, MJ and JFM conceived and planned this study. ANS, FC, DR, MJ and JFM designed the
bias assessment framework. ANS, HF and IP screened and extracted studies. ANS made
tables and figures. ANS wrote the first draft of the manuscript and all authors contributed to
subsequent revisions.

399

400 References

- 401
- 4021Minta, A. A. et al. Progress Toward Regional Measles Elimination Worldwide, 2000-2021.403MMWR Morb Mortal Wkly Rep **71**, 1489-1495 (2022).
- 404 <u>https://doi.org:10.15585/mmwr.mm7147a1</u>
- 4052Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a406systematic analysis for the Global Burden of Disease Study 2019. Lancet **396**, 1204-1222 (2020).407https://doi.org:10.1016/s0140-6736(20)30925-9
- 4083Keja, K., Chan, C., Hayden, G. & Henderson, R. H. Expanded programme on immunization. World409Health Stat Q 41, 59-63 (1988).
- 4 Hughes, S. L. *et al.* The effect of time since measles vaccination and age at first dose on measles vaccine effectiveness A systematic review. *Vaccine* 38, 460-469 (2020).
 412 https://doi.org:10.1016/j.vaccine.2019.10.090
- 4135Kumru, O. S. *et al.* Vaccine instability in the cold chain: mechanisms, analysis and formulation414strategies. *Biologicals* 42, 237-259 (2014). https://doi.org/10.1016/j.biologicals.2014.05.007
- 415 6 Mutsaerts, E. *et al.* Safety and Immunogenicity of Measles Vaccination in HIV-Infected and HIV416 Exposed Uninfected Children: A Systematic Review and Meta-Analysis. *EClinicalMedicine* 1, 28417 42 (2018). https://doi.org:10.1016/j.eclinm.2018.06.002
- 418 7 Winter, A. K. *et al.* Benefits and Challenges in Using Seroprevalence Data to Inform Models for
 419 Measles and Rubella Elimination. *J Infect Dis* 218, 355-364 (2018).
 420 https://doi.org:10.1093/infdis/iiv137
- 420 <u>https://doi.org:10.1093/infdis/jiy137</u>
 421 8 Cutts, F. T. & Hanson, M. Seroepidemiology: an underused tool for designing and monitoring vaccination programmes in low- and middle-income countries. *Trop Med Int Health* 21, 1086423 1098 (2016). <u>https://doi.org:10.1111/tmi.12737</u>
- 424 9 Lutz, C. S. *et al.* Comparison of measles IgG enzyme immunoassays (EIA) versus plaque
 425 reduction neutralization test (PRNT) for measuring measles serostatus: a systematic review of
 426 head-to-head analyses of measles IgG EIA and PRNT. *BMC Infect Dis* 23, 367 (2023).
 427 https://doi.org:10.1186/s12879-023-08199-8
- 42810Hutse, V. et al. Oral fluid for the serological and molecular diagnosis of measles. Int J Infect Dis42914, e991-997 (2010). https://doi.org:10.1016/j.ijid.2010.06.009
- 43011World Bank. The World by Income and Region, <<u>https://datatopics.worldbank.org/world-</u>431development-indicators/the-world-by-income-and-region.html> (2021).

432	12	Sterne, J. A. et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of				
433		interventions. <i>BMJ</i> 355 , i4919 (2016). <u>https://doi.org:10.1136/bmj.i4919</u>				
434	13	World Health Organization. Manual for the Laboratory-based Surveillance of Measles, Rubella,				
435		and Congenital Rubella Syndrome, < <u>https://cdn.who.int/media/docs/default-</u>				
436		source/immunization/vpd_surveillance/lab_networks/measles_rubella/manual/chapter-9.pdf>				
437	14	Cutts, F. T. <i>et al.</i> Immunogenicity of high-titer Edmonston-Zagreb measles vaccine in human				
438		immunodeficiency virus-infected children in Kinshasa, Zaire. J Infect Dis 167, 1418-1421 (1993).				
439		https://doi.org:10.1093/infdis/167.6.1418				
440	15	WHO. WHO/UNICEF estimates of national immunization coverage,				
441		<https: immunization-analysis-<="" immunization-vaccines-and-biologicals="" td="" teams="" www.who.int=""></https:>				
442		and-insights/global-monitoring/immunization-coverage/who-unicef-estimates-of-national-				
443		<u>immunization-coverage</u> > (2022).				
444	16	Eilertson, K. E., Fricks, J. & Ferrari, M. J. Estimation and prediction for a mechanistic model of				
445		measles transmission using particle filtering and maximum likelihood estimation. Stat Med 38,				
446		4146-4158 (2019). <u>https://doi.org:10.1002/sim.8290</u>				
447	17	Carcelen, A. C. et al. Leveraging a national biorepository in Zambia to assess measles and rubella				
448		immunity gaps across age and space. Sci Rep 12, 10217 (2022). https://doi.org:10.1038/s41598-				
449		022-14493-3				
450	18	Ministry of Health Zambia. Zambia Population-based HIV Impact Assessment (ZAMPHIA) 2016:				
451		Final Report. (Lusaka, Ministry of Health, February 2019).				
450						

453 Tables

454

455 **Table 1. Overall and categorical bias classifications.**

456 Results of bias assessment in each of three categories (study selection of participants,

457 measurement tool and classification of immunity, and reporting of results), and mean level of 458 bias per study.

459

Level of bias	Mean	Study selection of participants	Measurement tool and classification of immunity	Reporting of results
Low	12	15	19	20
Moderate	129	181	130	63
Severe	58	23	46	70
Critical	22	2	26	18

460

461

Figures



505 Figure 2. Number of serosurveys with data included per country.

506 Map of number of studies per country with available data identified by systematic review. 507



510 Figure 3. Measles seroprevalence by time period and overall bias level.

511 Beeswarm plot of measles seroprevalence by time period. Each point represents one country-512 year of data per study and are colored by overall bias level. Black lines represent the median

513 observation across each decade.

514



516 Figure 4. Overall bias level by MCV1 coverage and annual measles incidence.

517 Each point represents each country-year represented across all studies, colored by overall bias 518 level, by MCV1 coverage and annual estimated measles incidence.

519

